Type

Range

Units

Status

Start Date

End Date

Financing

Study Design

Homepage

Partner

Brief description/objective

The study aims to collect real-world data on treatment
patterns and decision points for treatment in patients with
coronary artery disease (CAD) or symptomatic peripheral
artery disease (PAD) treated with rivaroxaban 2.5 mg[BID]
for the prevention of atherothrombotic events in adult
patients at high risk of ischaemic events and to describe
outcomes of an antithrombotic regime based on dual
pathway inhibition (vascular dose of rivaroxaban 2.5 mg
[BID] plus low-dose ASA [OD]) across the broad range of
patient risk profiles encountered in routine clinical practice.
The primary objective in this study is:
• to describe treatment patterns in CAD or PAD
patients treated with rivaroxaban 2.5 mg [BID] plus
ASA 75-100 mg [OD] in routine clinical practice